Flavonol‐ruthenium complexes as antioxidant and anticancer agents

IF 3.6 4区医学 Q2 CHEMISTRY, MEDICINAL

ChemMedChem Pub Date : 2024-09-12 DOI:10.1002/cmdc.202400313

Tzenge-Lien Shih, Ting-Wei Wu, Yi-Cheng Chu, Chuan-Hsin Chang, Yu-Hui Hsieh, Mei-Hsin Tang, Pei-Hsuan Hsu, Jih-Jung Chen

引用次数: 0

Abstract

Flavonol‐metal complexes can enhance the biological activity of flavonols. Inspired by the potential of ruthenium‐based drugs in pharmaceutical applications, seven flavonol‐Ru (II) complexes were synthesized to evaluate their biological activities. Among these compounds, compounds 8, 11, and 12 showed potent antioxidant activities. Compound 12 exhibited superior anti‐inflammatory activity to natural quercetin, which served as a positive control. This study is the first to report the free radical scavenging abilities and antioxidant activity of flavonol‐Ru (II) complexes. Furthermore, compound 12 demonstrated comparable efficacy to 5‐FU against human non‐small‐cell lung cancer cells (A549). These results strongly support the potential of flavonol‐Ru (II) agents.

查看原文本刊更多论文

作为抗氧化剂和抗癌剂的黄酮醇钌复合物

黄酮醇-金属配合物可以增强黄酮醇的生物活性。受钌类药物在医药应用中的潜力启发，研究人员合成了七种黄酮醇-钌 (II) 复合物，以评估它们的生物活性。在这些化合物中，化合物 8、11 和 12 具有很强的抗氧化活性。化合物 12 的抗炎活性优于作为阳性对照的天然槲皮素。该研究首次报道了黄酮醇-Ru (II) 复合物清除自由基的能力和抗氧化活性。此外，化合物 12 对人类非小细胞肺癌细胞 (A549) 的疗效与 5-FU 相当。这些结果有力地证明了黄酮醇-Ru (II) 药剂的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.